The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation

The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective obser...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2024-07, Vol.115 (7), p.2384-2395
Main Authors: Shimazu, Yutaka, Kanda, Junya, Suzuki, Kazuhito, Wada, Akinori, Kikuchi, Taku, Ikeda, Takashi, Tsukada, Nobuhiro, Miwa, Akiyoshi, Itagaki, Mitsuhiro, Kako, Shinichi, Nishiwaki, Kaichi, Ota, Shuichi, Fujiwara, Shin‐ichiro, Kataoka, Keisuke, Doki, Noriko, Sawa, Masashi, Hiramoto, Nobuhiro, Nishikawa, Akinori, Imai, Toshi, Ichinohe, Tatsuo, Kanda, Yoshinobu, Atsuta, Yoshiko, Kawamura, Koji
Format: Article
Language:English
Subjects:
Adult
Age
Aged
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
Autografts
autologous stem cell transplantation
CD38 antigen
Chi-square test
Confidence intervals
daratumumab
Female
Gender
Hematopoietic Stem Cell Transplantation - methods
Humans
Male
Medical prognosis
Middle Aged
Monoclonal antibodies
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Multivariate analysis
Original
ORIGINAL ARTICLE
Prognosis
Progression-Free Survival
response
Retrospective Studies
Software packages
Stem cell transplantation
Transplantation, Autologous
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara– group) and those administered Dara (Dara+ group), the 1‐year progression‐free survival (PFS) rates were 87.4% and 77.3% and the 1‐year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age
ISSN:1347-9032
1349-7006
1349-7006
DOI:10.1111/cas.16198